Article

Rheumatology Journal Club Twitter Chat Dec. 10

The Rheumatology Journal Club will host its next Twitter chat Thursday, Dec. 10 with two sessions beginning at 4 and 10 p.m. EST.

The Rheumatology Journal Club will host its next Twitter chat Thursday, Dec. 10 with two hour-long sessions beginning at 4 p.m. and 10 p.m. EST. The Dec. 10 session will focus on three abstracts selected by Rheumatology Journal Club followers polled in Twitter.

The three abstracts include:[[{"type":"media","view_mode":"media_crop","fid":"44416","attributes":{"alt":"","class":"media-image media-image-right","id":"media_crop_2983203835319","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"4962","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"font-size: 13.008px; line-height: 1.538em; float: right;","title":" ","typeof":"foaf:Image"}}]]

  • ACR/ARHP 2015 Abstract 505:  Comparative Effectiveness and Time to Response Among Abatacept, Adalimumab, Certolizumab, Etanercept, Infliximab, Rituximab and Tocilizumab in a Real World Routine Care Registry
  • ACR/ARHP 2015 Abstract 1075:  The Scleroderma Lung Study II (SLS II) Shows That Both Oral Cyclophosphamide (CYC) and Mycophenolate Mofitil (MMF) Are Efficacious in Treating Progressive Interstitial Lung Disease (ILD) in Patients with Systemic Sclerosis (SSc)
  • ACR/ARHP 2015 Abstract 3223:  Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

The Rheumatology Journal Club was launched in January 2015 by Christopher E. Collins, MD, associate professor of medicine at Georgetown University Medical Center and a member of the Rheumatology Network Editorial Board. "We're a group that is interested in applying the power of Twitter to rheumatology education through Twitter," Dr. Collins writes on the Rheumatology Journal Club website.

Each journal club Twitter chat includes:

  • Open access link to the featured article
  • Invitation to the author of the featured study to participate in the chat
  • An introductory blog post
  • Physician moderator
  • Follow-up blog post
  • Summary of the chat session which will be included on the PubMed Commons portion of each discussed article.

The first four journal club chats included 133 participants from 31 countries. The majority of participants were rheumatologists, but there were physicians from eight medical specialities including nephrology, gastroenterology and geriatrics.

An analysis recently conducted by the Rheumatology Journal Club showed that the mean number of total tweets during each of the journal clubs was 493 (385 unique tweets, 108 re-tweets) with an average of 197 tweets (166 unique tweets, 31 re-tweets) during each of the live one hour sessions.

In addition to Dr. Collins (@RheumPearls), the journal club includes Paul Sufka (@psufka), MD, a rheumatologist with HealthPartners Medical Group and Regions Hospital in St. Paul, Minn.; Suleman Bhana (@DrBhana), MD, a rheumatologist in the Hudson Valley area of New York; Aruni Jayatilleke (@rheumed), MD, assistant professor of medicine at Drexel University College of Medicine; and, Jonathan Hausmann (@hausmannMD), MD, a pediatric and adult rheumatology fellow at Boston Children’s Hospital and Beth Israel Deaconess Medical Center.

For more information about the Rheumatology Journal Club, visit @RheumJC on Twitter or email rheumjc@gmail.com.

 

 

Related Videos
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Uncovering the Role of COVID-19 in Rheumatic Disease, with Leonard Calabrese, DO
© 2024 MJH Life Sciences

All rights reserved.